Surprisingly, no synergistic effects of RNR inhibition with purine analogs and ara-C were observed demonstrating the importance of pyrimidine de novo synthesis in the response rates of AML patients to ara-C (Figure 3C,F) [109]. Here, NR2E3 is linked to acute myeloid leukemia.